Gizelle Baker
      OUR PEOPLE

      Dr. Gizelle Baker

      PhD in Biometry and Epidemiology

      Vice President Global Scientific Engagement

      Contact

      Gizelle Baker is Vice President of Global Scientific Engagement leading the team in communicating Philip Morris International's science towards a smoke-free future.

      Originally from Canada, Gizelle pursued her passion for science and public health at the Medical University of South Carolina in the USA – where she obtained a PhD in Biometry and Epidemiology. Before joining PMI, Gizelle held several leadership positions at Pfizer, including Vice President of Medical Affairs for Emerging Markets and Senior Director of Worldwide Medical Operations. 

      Now at PMI, Gizelle is responsible for the scientific engagement strategy and ensures the company's scientific communications are accurate, transparent, and always based on the latest evidence. Gizelle is a key figure in the  tobacco harm reduction movement and a talented public speaker who also uses her platform to promote women in leadership. As she steers her teams to inform all corners of the world on PMI's science, she builds bridges between academia, stakeholders, policy makers, and the public. As Vice President of the Scientific Engagement department, Gizelle is inspired by her team every day.

      To put it in her own words:

      "I can come up with a hundred solutions to a problem, but when people carve their own route to their goals it will lead to all of our success. That's what I love to see."

      Latest Publications

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.